This article was originally published in The Tan Sheet
Revenues during the firm's second quarter grew 17.8 % to $19.5 mil., fueled by the strong performance of new the products which more than offset a decline from the discontinuation of Ester-C, the Chatsworth, Calif.-based firm says. The nutritional products company adds it is well-positioned to enter the international marketplace, and is benefiting from the diversification of its business through the recent acquisition of MRI (1"The Tan Sheet" June 18, 2007, p. 7). Operating income jumped 172.9% during the quarter to $737,000 while net income was $4.2 mil. compared to $100,000 in the year-ago period, the firm notes...
You may also be interested in...
Dietary supplement manufacturer Natrol expands its sports nutrition product offerings with its $8 million cash acquisition of Medical Research Institute
Can a false-claims suit be filed if doctors have different opinions about whether a treatment was necessary? The Supreme Court won’t say.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.